Tata India Pharma & Healthcare Fund
NAV
₹39.74
as of 21 Aug 2026
Tata India Pharma & Healthcare Fund is an open-ended Sectoral/ Thematic scheme from Tata Mutual Fund managing ₹1,541 crore (as of 31 Jul 2026). Its Direct-plan NAV is ₹39.74 as of 21 Aug 2026. The expense ratio is 0.64% a year. Managed by Rajat Srivastava. This page is factual data only — it carries no rating and no recommendation.
Key facts
- Expense ratio
- 0.64% / yr
- as of 30 Jun 2026
- Fund size
- ₹1,541 crore
- as of 31 Jul 2026
- Exit load
- 0.25%
- SIP available
- Yes
- Launched
- 28 Dec 2015
- ISIN
- INF277K019A3
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from NYVO’s own NAV data.
Rebased to 100data to 20 Aug 2026Benchmark: Nifty 500 Healthcare TRI
Tata India Pharma & Healthcare Fund
₹207
+107% on ₹100 over 5.0 yrs
Sectoral/ Thematic average
₹210
+110% on ₹100 over 5.0 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | 6.99% | 6.78% | +0.21 |
| 6 months | 13.08% | 3.68% | +9.40 |
| 1 year | 9.68% | 6.07% | +3.61 |
| 3 years (CAGR) | 20.28% | 16.01% | +4.27 |
| 5 years (CAGR) | 15.51% | 15.20% | +0.31 |
Category average across 119 funds, as of 21 Aug 2026. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible — read that number first.
1-year holding periods
- Worst
- -9.7%
- Median
- 13.5%
- Best
- 61.5%
49 windows over the last 60 months, stepped monthly; 78% ended positive. Worst window began 1 Sept 2021. Windows overlap — this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 19.4%
- Median
- 23.0%
- Best
- 26.5%
25 windows over the last 60 months, stepped monthly; 100% ended positive. Worst window began 2 Aug 2021. Windows overlap — this is the range of past start dates, not a probability of anything.
Risk, measured
- Sharpe ratio (3Y)
- 0.88
- Sharpe ratio (5Y)
- 0.63
- Sortino ratio (3Y)
- 1.48 vs category 1.55
- Standard deviation (3Y)
- 16.38%
- Beta (3Y)
- 0.99
- Alpha (3Y)
- -0.81%
- Deepest fall (5Y)
- -16.17%
Distance below its own peak
Every dip below 0 is the fund trading under a previous high — how deep and for how long is what a drawdown feels like.
Deepest fall
-16.2%
Right now
-0.9% below peak
Ahead of its benchmark in 50% of months (window: 3y, monthly) — benchmark: Nifty 500 Healthcare TRI, name shown only.
Where the money actually is
Equity
99.1%
Cash
0.9%
Whole-portfolio split, as of 31 Jul 2026.
What it owns
39 positions · top 10 = 52.8%
Market-cap mix
Large 23.4%Mid 32.0%Small 42.8%Other 1.8%
as of 31 Jul 2026
Holdings by sector
Healthcare(10 in top 10)92.2%
- Sun Pharmaceuticals Industries Ltd8.59%
- Divi's Laboratories Ltd6.36%
- HealthCare Global Enterprises Ltd5.85%
- Abbott India Ltd5.63%
- Rainbow Childrens Medicare Ltd4.90%
- GlaxoSmithKline Pharmaceuticals Ltd4.66%
- Cipla Ltd4.53%
- Dr Reddy's Laboratories Ltd4.25%
- Max Healthcare Institute Ltd Ordinary Shares4.07%
- Apollo Hospitals Enterprise Ltd3.90%
- Basic Materials5.8%
- Consumer Defensive1.1%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 31 Jul 2026. Portfolio turnover 11.2% vs category 37.3% a year.
The businesses it owns
- P/E (trailing)
- 42.0 vs category 25.8
- P/B
- 6.3 vs category 3.8
- Dividend yield
- 0.9% vs category 1.1%
- Net margin
- 16.1% vs category 15.4%
- Earnings growth
- 15.4%
- Avg market cap
- ₹49,733 crore
Money in, money out
- Net flow, 12 months
- +₹89 cr
- Net flow, 3 months
- +₹52 cr
as of 31 Jul 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of Tata India Pharma & Healthcare Fund?
- ₹39.74 per unit as of 21 Aug 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of Tata India Pharma & Healthcare Fund?
- 0.64% a year for the Direct plan, as of 30 Jun 2026.
- How large is Tata India Pharma & Healthcare Fund?
- ₹1,541 crore under management as of 31 Jul 2026, in the Sectoral/ Thematic category.
- How risky is Tata India Pharma & Healthcare Fund?
- Its SEBI Riskometer reading is "Very High Risk". One sector, one story. The most-launched shelf on the map, by far.
- What are the 5-year returns of Tata India Pharma & Healthcare Fund?
- 15.51% a year over the last 5 years (Direct plan, CAGR), against a Sectoral/ Thematic average of 15.20%. Past returns do not predict future returns.
- What is the worst 3-year return of Tata India Pharma & Healthcare Fund?
- 19.4% a year — the weakest of 25 overlapping 3-year holding periods, beginning 2 Aug 2021. The median was 23.0% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages Tata India Pharma & Healthcare Fund?
- Rajat Srivastava, managing this fund for 1.9 years.
Where this fund sits
Its shelf, all funds
St · Sectoral / thematic →
One sector, one story. The most-launched shelf on the map, by far.
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund — growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Sectoral/ Thematic funds
- ICICI Prudential India Opportunities Fund₹38,299 crore
- ICICI Prudential Business Cycle Fund₹16,123 crore
- Tata Digital India Fund₹10,214 crore
- Tata Ethical Fund₹3,865 crore
- Kotak Banking and Financial Services Fund₹1,556 crore
- BANDHAN Infrastructure Fund₹1,545 crore
- Invesco India Infrastructure Fund₹1,540 crore
- UTI Quant Fund₹1,539 crore
Data: NYVO research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (Nifty 500 Healthcare TRI) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.